Theravance Biopharma, Inc. financial data

Symbol
TBPH on Nasdaq
Location
George Town, Grand Cayman, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 663% % 25%
Return On Equity 15% %
Return On Assets 7.6% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50,672,431 shares 3%
Common Stock, Shares, Outstanding 50,672,000 shares 3%
Entity Public Float $334,900,000 USD -27%
Common Stock, Value, Issued $1,000 USD
Weighted Average Number of Shares Outstanding, Basic 50,520,000 shares 3%
Weighted Average Number of Shares Outstanding, Diluted 51,908,000 shares 5.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $80,327,000 USD 27%
Research and Development Expense $39,507,000 USD 8.2%
Operating Income (Loss) $32,814,000 USD 25%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $47,240,000 USD 71%
Income Tax Expense (Benefit) $17,896,000 USD 105%
Net Income (Loss) Attributable to Parent $29,344,000 USD
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $174,773,000 USD 648%
Assets, Current $354,697,000 USD 205%
Property, Plant and Equipment, Net $6,257,000 USD -20%
Operating Lease, Right-of-Use Asset $25,450,000 USD -13%
Other Assets, Noncurrent $25,191,000 USD 237%
Assets $415,460,000 USD 17%
Accounts Payable, Current $2,213,000 USD 52%
Employee-related Liabilities, Current $10,330,000 USD 32%
Liabilities, Current $37,407,000 USD 60%
Operating Lease, Liability, Noncurrent $33,681,000 USD -17%
Other Liabilities, Noncurrent $313,000 USD -94%
Accumulated Other Comprehensive Income (Loss), Net of Tax $32,000 USD -36%
Retained Earnings (Accumulated Deficit) $920,651,000 USD 3.1%
Stockholders' Equity Attributable to Parent $232,681,000 USD 25%
Liabilities and Equity $415,460,000 USD 17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $43,039,000 USD
Net Cash Provided by (Used in) Financing Activities $854,000 USD 50%
Net Cash Provided by (Used in) Investing Activities $30,632,000 USD 80%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 50,672,000 shares 3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $72,817,000 USD 410%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $175,609,000 USD 625%
Deferred Tax Assets, Valuation Allowance $435,543,000 USD 1.3%
Deferred Tax Assets, Gross $451,588,000 USD 0.96%
Operating Lease, Liability $49,820,000 USD 1.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $29,326,000 USD
Lessee, Operating Lease, Liability, to be Paid $62,890,000 USD -4.8%
Property, Plant and Equipment, Gross $29,819,000 USD -2.7%
Operating Lease, Liability, Current $10,914,000 USD 160%
Lessee, Operating Lease, Liability, to be Paid, Year Two $11,414,000 USD 4.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $11,218,000 USD 188%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) $1,852,000 USD -261%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $13,070,000 USD 29%
Lessee, Operating Lease, Liability, to be Paid, Year Three $11,682,000 USD 4.3%
Deferred Tax Assets, Operating Loss Carryforwards $154,476,000 USD 0.82%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 230,000 shares 0%
Unrecognized Tax Benefits $83,658,000 USD 5.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four $11,739,000 USD 2.3%
Additional Paid in Capital $1,153,299,000 USD 1.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $16,045,000 USD -8%
Share-based Payment Arrangement, Expense $19,821,000 USD -7.3%
Interest Expense $2,429,000 USD -49%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%